<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568450</url>
  </required_header>
  <id_info>
    <org_study_id>GL2907-101</org_study_id>
    <nct_id>NCT01568450</nct_id>
  </id_info>
  <brief_title>A Open-label, Single-dose Study to Investigate The Pharmacokinetics Between a GL2907 XL and Oxycontin CR Tab. 10mg in Healthy Male Volunteers</brief_title>
  <acronym>GL2907-101</acronym>
  <official_title>A Randomized, Open-label, Single-dose, Crossover Study to Investigate The Pharmacokinetics Between a GL2907 XL and Oxycontin CR Tab. 10mg in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GL Pharm Tech Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GL Pharm Tech Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to compare the pharmacokinetic characteristics of
      GL2907 XL 20mg tablet and Oxycontin CR 10mg tablet.

      GL2907 XL 20mg tablet is controlled released formulation which is made by GL Pharm Tech.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>48hr</time_frame>
    <description>Pharmacokinetic of Oxycodone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24h)</measure>
    <time_frame>24 hr</time_frame>
    <description>Pharmacokinetic of Oxycodone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>48 hr</time_frame>
    <description>Pharmacokinetic of Oxycodone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>48 hr</time_frame>
    <description>Pharmacokinetic of Oxycodone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>48 hr</time_frame>
    <description>Pharmacokinetic of Oxycodone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>48 hr</time_frame>
    <description>Pharmacokinetic of Oxycodone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Monitoring</measure>
    <time_frame>27 days</time_frame>
    <description>Adverse Event, Vital sign, 12-lead ECG, Physical Exam, Laboratory test</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GL2907 XL 20mg (Oxycodone 20mg, fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GL2907 XL 20mg (Oxycodone 20mg, after high fat meal)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxycontin CR 10mg (Oxycodone 10mg, fasted)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Oxycodone XL 20mg(20mg once a day, fasted)</description>
    <arm_group_label>GL2907 XL 20mg (Oxycodone 20mg, fasted)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Oxycodone XL 20mg/day(20mg once a day, after high fat meal)</description>
    <arm_group_label>GL2907 XL 20mg (Oxycodone 20mg, after high fat meal)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Oxycodone 20mg/day (10mg twice a day, fasted)</description>
    <arm_group_label>Oxycontin CR 10mg (Oxycodone 10mg, fasted)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20~45 years old, Healthy Adult Male Subject

          -  ≥ 50kg(Body Weight) and Ideal Body Weight ≤ ±20%

        Exclusion Criteria:

          -  ALT or AST &gt; 1.25(Upper Normal Range)

          -  Total Bilirubin &gt; 1.5 (Upper Normal Range)

          -  BUN or Creatinine &gt; Normal Range

          -  Systolic BP &gt; 160mmHg or &lt; 80mmHg, Diastolic BP &gt; 100mmHg or &lt; 50mmHg
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doo-Yeoun Cho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AJOU University Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggido</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>January 25, 2013</last_update_submitted>
  <last_update_submitted_qc>January 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxycodone, controlled release formulation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

